Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study
Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Dennis Cooper(Yale Cancer Center), A. Dimitrios Colevas(Cancer Institute (WIA)), Jeffrey F. Krane(University of California, Los Angeles), Rosemary Costello(Dana-Farber Cancer Institute), Philip C. Amrein(Massachusetts General Hospital), Bonnie S. Glisson(The University of Texas MD Anderson Cancer Center), Linda Weeks(Dana-Farber Cancer Institute)
Cited by 262
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926